Received Mar 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | 1 | Y011819 | — |
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | 2 | Y011819 | — |
No side effects or symptoms reported; received a second dose of CAPVAXIVE. HCP states the patient received their first dose on 10/21/2024 and received their second dose 02/25/2025; This spontaneous report was received from a pharmacist and refers to a 52-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 21-OCT-2024, the patient was vaccinated with a first dose of Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) Injection 168 mcg/ml (lot #Y011819, expiration date: 01-OCT-2025), 0.5 ml for prophylaxis by health professional (route of administration was not reported). On 25-FEB-2025, the patient was vaccinated with a second dose of Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) Injection 168 mcg/ml (lot #Y011819, expiration date: 01-OCT-2025), 0.5 mL for prophylaxis by health professional (route of administration was not reported) (Extra dose administered). No side effects or symptoms reported. No additional information provided. No additional adverse event (AE) or product quality complaint (PQC). At the reporting time, the outcome of the event was unknown. The action taken with Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) was not applicable.; Sender's Comments: Priority : 5 , Is case serious : No , MNSC number : 02759920-02759919 , CLIC number : , ESTAR number : , IRMS number : 500UW00000UfrwnYAB|03032025230058|1459 , Central date : 2025-03-04 , Classification : DMC, Attachment description : NSC Call , Safety case number : 2258801 , MNSC case number : 02759920 , MNSC interaction number : 02759919 , Integration log UniqueID : 500UW00000UfrwnYAB|03032025230058|1459 , Service cloud CaseID : 500UW00000UfrwnYAB
Comments: not reported